Navigation Links
Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology
Date:9/4/2008

Updated Survival Data for Ipilimumab to be Presented

PRINCETON, N.J., Sept. 4 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today that nine clinical abstracts for ipilimumab, an investigational anti-CTLA-4 antibody, in melanoma are scheduled to be the subject of presentations at the 33rd Congress of the European Society for Medical Oncology (ESMO) being held September 12-16, 2008 in Stockholm. Many of the following abstracts will include updated one-year survival data from three Phase 2 studies (008, 022 and 007) in previously treated patients with advanced metastatic melanoma:

Ipilimumab Presentations in Advanced Melanoma

-- "Efficacy and safety of patients with advanced melanoma treated with ipilimumab with or without the addition of prophylactic budesonide" (Abstract #783P) I. Ron - Poster presentation from 12:45 p.m. to 1:45 p.m. local time on Saturday, September 13, 2008.

-- "Treatment guidelines for the management of immune-related adverse events in patients treated with ipilimumab, an anti-CTLA4 therapy" (Abstract #787P) K. Chin - Poster discussion from 12:45 p.m. to 1:45 p.m. local time on Saturday, September 13, 2008.

-- "Ipilimumab-mediated patterns of response in patients with pretreated, advanced melanoma" (Abstract #784P) K. Harmankaya - Poster presentation from 12:45 p.m. to 1:45 p.m. local time on Saturday, September 13, 2008.

-- "Clinical activity of ipilimumab in patients with advanced melanoma and brain metastases" (Abstract #786P) J. S. Weber - Poster presentation from 12:45 p.m. to 1:45 p.m. local time on Saturday, September 13, 2008.

-- "Ipilimumab 10 mg/kg induction dosing promotes T-cell activation in patients with advanced melanoma" (Abstract #785P) A. Hoos - Poster presentation and discussion from 12:45 p.m. to 1:45 p.m. local time on Saturday, September 13, 2008.

-- "Effect of dose on efficacy and safety in ipilimumab-treated patients with advanced melanoma - results from a Phase 2, randomized, dose-ranging study" (Abstract #769O) C. Lebbe - Oral presentation from 3:30 p.m. to 5:30 p.m. local time on Monday, September 15, 2008.

-- "Efficacy and safety of treatment-naive and previously treated patients with advanced melanoma receiving ipilimumab" (Abstract #778PD) R. Ridolfi - Poster discussion from 12:30 p.m. to 1:30 p.m. local time on Monday, September 15, 2008.

-- "Efficacy and safety of ipilimumab in patients with advanced melanoma who had progressed on one or more prior therapies: results from a single-arm, multicenter study" (Abstract #776PD) M. Maio - Poster discussion from 12:30 p.m. to 1:30 p.m. local time on Monday, September 15, 2008.

-- "Prolonged stable disease in ipilimumab-treated patients with advanced melanoma who have progressed on prior anticancer therapies" (Abstract #768O) V. Chiarion Sileni - Oral presentation from 3:30 p.m. to 5:30 p.m. local time on Monday, September 15, 2008.

More information about the ESMO Congress may be found at http://www.esmo.org.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. More than 40 of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with seven of the most advanced product candidates currently in Phase 3 clinical trials or the subject of regulatory applications for marketing authorization. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at http://www.medarex.com.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.


'/>"/>
SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
2. Medarex to Receive Milestone Payment from Amgen
3. Medarex Announces Ipilimumab Program Continues to Move Forward
4. Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
5. Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
6. Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis
7. Medarex Highlights Strength in Antibody Development and Underlying Pipeline Strategy at R&D Day Event in New York City
8. Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-PD-L1 Antibody, MDX-1105
9. Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... 21, 2017 Halo Labs announces the launch ... analysis system called the Horizon at PEGS 2017 in ... new system analyzes sub visible particulate matter in biopharmaceutical ... screening as early as candidate selection and pre-formulation. ... contract research organization Elion Labs for system ...
(Date:4/20/2017)... April 20, 2017 Research and ... Biosimilar Pipeline and Market Prospects: Addressing Production Complexities Through ... their offering. ... "Global Biosimilar Pipeline and Market Prospects: Overcoming Production ... an in-depth assessment of the current trends in the ...
(Date:4/20/2017)... Inc ., a digital health company focused on modernizing and ... $25 million in Series B funding led by Qiming US ... Seattle that is part of a broader family ... included participation from SR One , who led ZappRx,s ... Google Ventures). As part of the financing, Mark McDade ...
Breaking Medicine Technology:
(Date:4/25/2017)... Vegas, NV (PRWEB) , ... April 25, 2017 ... ... can now choose a modern procedure that achieves results in a fraction of ... in Las Vegas, NV, with Significance Dental Specialists, now offers this revolutionary ...
(Date:4/25/2017)... ... , ... Back Pain Centers of America (BPC), which connects people ... their area, announces the launch of a new and proprietary customer relationship management (CRM) ... reputable physicians to help them with back or neck pain and helps to match ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... predictive analytics to its patient care management module. Using this new feature, sleep ... patient has been initiated on continuous positive airway pressure (CPAP), oral, or other ...
(Date:4/25/2017)... ... April 25, 2017 , ... Vetoquinol USA® , a ... UCII, part of the EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event ... the immunologic level. , The scientifically-developed Flexadin UCII supports the body’s normal repair ...
(Date:4/24/2017)... ... April 24, 2017 , ... LG CNS Healthcare ... Device (BYOD) capabilities at Telehealth 2.0, the American Telemedicine Association’s national conference. , ... medical devices with a pre-programmed tablet in a remarkably easy-to-use kit for patients. ...
Breaking Medicine News(10 mins):